North America phenylketonuria treatment market accounted for USD 436.00Â million in 2026 and is expected to grow at a CAGR of 9% throughout the forecast period. The market is driven by advancements in therapeutic options and a growing awareness of the condition. As healthcare providers and patients alike become more informed about phenylketonuria, the demand for effective treatments seems to be on the rise. These trends were evaluated by our Senior Research Analyst, Deepa Pandey, to curate this well-researched report. Her analysis benefits pharmaceutical producers, distributors, medical professionals, and stakeholders in performing competitive analysis and informed decision-making.